Why Herbalife, Steel Partners Holdings, and Achillion Pharmaceuticals Jumped Today

Monday was an up-and-down day on Wall Street, as major stock market benchmarks moved on both sides of unchanged before settling down on the day. Biotech stocks weighed especially hard on the Nasdaq, but that didn't keep some stocks from scoring impressive gains. Herbalife (NYSE: HLF  ) , Steel Partners Holdings (NYSE: SPLP  ) , and Achillion Pharmaceuticals (NASDAQ: ACHN  ) were among the biggest winners today.

Herbalife gained 7% as activist investor Carl Icahn gained control of three more director seats on the multi-level marketing company's board. With an investigation into the company's practices having recently begun, Herbalife stock is well off its highs as fearful investors worry that the company could have its business model threatened. Yet Icahn remains optimistic that Herbalife represents a solid value and has plenty of growth potential ahead. Moreover, Herbalife also likely gained from news that peer Nu Skin Enterprises (NYSE: NUS  ) avoided the brunt of potential damage from Chinese regulators, paying fines of less than $1 million in connection with its practices in the emerging-market nation.

Steel Partners Holdings rose 8% after the limited partnership announced that it would buy up to $49 million worth of its partnership units in a Dutch auction. The holding company is an interesting conglomeration of businesses in different industries, ranging from a combination well-completion and sports-services company to hot-dog giant Nathan's Famous, and it has historically traded at a value well below the sum total of its holdings. With the Dutch-auction tender offer, Steel Partners is aiming to boost its unit price while also giving it a chance to buy back partnership units at an attractive valuation.

Achillion Pharmaceuticals rose 7% after the biotech company got an upgrade from Maxim Group. The maker of the once-promising hepatitis-C treatment sovaprevir got crushed last fall, when the FDA chose not to lift a clinical hold on the drug that the agency had originally imposed earlier last year. Yet after that big drop, some believe that unlike other high-flying biotech stocks, Achillion represents a reasonable value at current prices. There's still plenty of risk given Achillion's historical inability to get promising treatments all the way through clinical trials, but with the stock down, analysts see it as a worthwhile gamble.

2 biotechs changing the way we treat cancer
The best way to play the biotech space is to find companies that shun the status quo and instead discover revolutionary, groundbreaking technologies. In the Motley Fool's brand-new FREE report "2 Game-Changing Biotechs Revolutionizing the Way We Treat Cancer," find out about a new technology that big pharma is endorsing through partnerships, and the two companies that are set to profit from this emerging drug class. Click here to get your copy today.

Read/Post Comments (0) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2888375, ~/Articles/ArticleHandler.aspx, 9/4/2015 8:37:44 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Dan Caplinger

Dan Caplinger has been a contract writer for the Motley Fool since 2006. As the Fool's Director of Investment Planning, Dan oversees much of the personal-finance and investment-planning content published daily on With a background as an estate-planning attorney and independent financial consultant, Dan's articles are based on more than 20 years of experience from all angles of the financial world.

Today's Market

updated 11 hours ago Sponsored by:
DOW 16,374.76 23.38 0.14%
S&P 500 1,951.13 2.27 0.12%
NASD 4,733.50 0.00 0.00%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

9/3/2015 4:00 PM
ACHN $7.55 Down +0.00 +0.00%
HLF $57.12 Down +0.00 +0.00%
Herbalife CAPS Rating: *
NUS $45.81 Down +0.00 +0.00%
Nu Skin Enterprise… CAPS Rating: **
SPLP $17.00 Down +0.00 +0.00%
Steel Partners Hol… CAPS Rating: No stars